Table 2. Univariate analysis of clinical factors on OS.
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Sex | |||
| Male | 1.904 | 0.539–2.220 | 0.804 |
| Female | 1 | ||
| Age (years) | |||
| <64 | 1.110 | 0.538–2.289 | 0.778 |
| ≥64 | 1 | ||
| Body mass reduction (kg) | |||
| <5 | 1.708 | 0.817–3.567 | 0.155 |
| ≥5 | 1 | ||
| Body mass index (kg/m2) | |||
| <18.5 | 1.903 | 0.841–4.310 | 0.123 |
| ≥18.5 | 1 | ||
| CEA | |||
| ≤5 | 1.402 | 0.657–2.992 | 0.382 |
| >5 | 1 | ||
| CA199 (U/mL) | |||
| <37 | 0.570 | 0.278–1.166 | 0.124 |
| ≥37 | 1 | ||
| Serum albumin | |||
| <35 | 0.235 | 0.082–0.671 | 0.007* |
| ≥35 | 1 | ||
| Tumor size (cm) | |||
| <3 | 2.810 | 1.358–5.815 | 0.005* |
| ≥3 | 1 | ||
| Tumor differentiation | |||
| Moderately or highly differentiated | 2.345 | 1.073–5.126 | 0.033* |
| Poorly differentiated | 1 | ||
| Tumor location | |||
| Medium or high location | 0.835 | 0.404–1.725 | 0.626 |
| Low location | 1 | ||
| TNM stage | |||
| I–II | 1.843 | 0.866–3.924 | 0.113 |
| III–IV | 1 | ||
| Infiltration depth | |||
| Early (TIS + T1) | 0.649 | 0.318–1.326 | 0.236 |
| Progress period (T2–T4) | 1 | ||
| Chemotherapy | |||
| Yes | 6.053 | 2.698–13.580 | 0.000* |
| No | 1 | ||
| Distant metastasis | |||
| Yes | 5.712 | 0.777–42.001 | 0.087 |
| No | 1 | ||
| Lymph node metastasis | |||
| Yes | 1.326 | 0.463–3.797 | 0.599 |
| No | 1 | ||
| Nerve invasion | |||
| Yes | 1.710 | 0.699–4.186 | 0.240 |
| No | 1 | ||
| Vascular tumor thrombus | |||
| Yes | 0.135 | 0.062–0.293 | 0.000* |
| No | 1 | ||
| NLR/PA | |||
| Low (<0.0947) | 0.181 | 0.074–0.442 | 0.000* |
| High (≥0.0947) | 1 | ||
| METTL11B expression | |||
| Low | 0.102 | 0.039–0.266 | 0.000* |
| High | 1 |
*, P<0.05, the difference was statistically substantial. OS, overall survival; CEA, carcinoembryonic antigen; HR, hazard ratio; METTL11B, methyltransferase-like protein 11B; NLR/PA, neutrophil lymphocyte ratio to prealbumin ratio; TNM stage, tumor (T), node (N), metastasis (M) stage; TIS, carcinoma in situ.